NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate… Nov 23, 2021
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion… Nov 23, 2021
Numinus CEO Payton Nyquvest Says Psychedelic Therapy Shouldn’t Be The ‘Last’ Option For Treatment Nov 21, 2021
